Patrick M Travis MD

Physician

3901 Parkway CirSte 100Springdale, AR 72762
Phone+1 479-587-1700
Fax+1 479-587-1366

Dr. Travis is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Travis' full profile Already have an account?

Education & Training

University of Arkansas for Medical SciencesFellowship, Hematology and Medical Oncology, 1992 - 1994
University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1990 - 1992
University of Arkansas For Medical Sciences College of MedicineClass of 1990

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

AR State Medical License 1990 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification ARIA oncology information system (for Medical Oncology), Varian Medical Systems, 2013-2017
CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Radiation Oncology), Varian Medical Systems, 2013-2017
CMS Meaningful Use Stage 2 Certification ARIA Oncology Information System (for Medical Oncology), Varian Medical Systems, 2013-2017

Clinical Trials

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients Start of enrollment: 2014 Mar 08
Completed
Phase 2
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
No longer available

Publications & Presentations

PubMed

Remote Therapeutic Monitoring and Infection-Related Health Care Resource Utilization in Patients With Hematologic Malignancies.
Benjamin A Derman, James H Essell, Mustafa S Ascha, Michael A Kolodziej, Lavi Kwiatkowsky
JCO Oncology Practice. 2026-04-10
2 citations
A phase 2 randomized study of modakafusp alfa as a single agent for patients with relapsed/refractory multiple myeloma.
Sarah A Holstein, Shebli Atrash, Hira Mian, Meletios A Dimopoulos, Fredrik Schjesvold
Blood. 2025-08-28
40 citations
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, o...
Jeff P. Sharman, Danielle M. Brander, Anthony R. Mato, Nilanjan Ghosh, Stephen J. Schuster
The Lancet. Haematology. 2021-04-01